会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 83. 发明申请
    • METHOD AND APPARATUS FOR LOCATING SPEECH KEYWORD AND SPEECH RECOGNITION SYSTEM
    • 用于定位语音关键词和语音识别系统的方法和装置
    • WO2008044582A1
    • 2008-04-17
    • PCT/JP2007/069409
    • 2007-09-27
    • SHARP KABUSHIKI KAISHALI, FengqinWU, YadongYANG, QinqtaoCHEN, Chen
    • LI, FengqinWU, YadongYANG, QinqtaoCHEN, Chen
    • G10L15/02G10L15/06
    • G10L15/02G10L15/10G10L15/142G10L2015/025G10L2015/088
    • It is an object of the present invention to provide a method and apparatus for locating a keyword of a speech and a speech recognition system. The method includes the steps of: by extracting feature parameters from frames constituting the recognition target speech, forming a feature parameter vector sequence that represents the recognition target speech; by normalizing of the feature parameter vector sequence with use of a codebook containing a plurality of codebook vectors, obtaining a feature trace of the recognition target speech in a vector space; and specifying the position of a keyword by matching prestored keyword template traces with the feature trace. According to the present invention, a keyword template trace and a feature space trace of a recognition target speech are drawn in accordance with an identical codebook. This causes resampling to be unnecessary in performing linear movement matching of speech wave frames having similar phonological feature structures. This makes it possible to improve the speed of location and recognition while ensuring the precision of recognition.
    • 本发明的目的是提供一种用于定位语音和语音识别系统的关键词的方法和装置。 该方法包括以下步骤:通过从构成识别目标语音的帧中提取特征参数,形成表示识别目标语音的特征参数向量序列; 通过使用包含多个码本向量的码本来归一化特征参数矢量序列,获得矢量空间中的识别目标语音的特征轨迹; 并通过将预先存储的关键字模板跟踪与特征跟踪相匹配来指定关键字的位置。 根据本发明,根据相同的码本绘制关键字模板跟踪和识别对象语音的特征空间轨迹。 这导致在执行具有相似的语音特征结构的语音波帧的线性移动匹配中,重新采样是不必要的。 这样可以提高位置和识别的速度,同时确保识别精度。
    • 90. 发明申请
    • THIOPHENOPYRIMIDINES
    • WO1997029110A1
    • 1997-08-14
    • PCT/EP1997000457
    • 1997-01-30
    • JANSSEN PHARMACEUTICA N.V.NEUROCRINE BIOSCIENCES INC.CHEN, ChenWEBB, Thomas, R.McCARTHY, James, R.MORAN, Terence, J.
    • JANSSEN PHARMACEUTICA N.V.NEUROCRINE BIOSCIENCES INC.
    • C07D495/04
    • C07D495/04
    • This invention concerns compounds of formula (I) including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein X is S, SO or SO2; R is NR R or OR ; R is C1-6alkyl, C1-6alkyloxy or C1-6alkylthio; R is hydrogen, C1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfoxy or C1-6alkylthio; R is hydrogen, C1-6alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl or C1-6alkyloxyC1-6alkyl; R is C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, Ar CH2, C1-6alkyloxy-C1-6alkyl, hydroxyC1-6alkyl, C3-6alkenyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6 alkyl, morpholinyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl, C1-6alkyl substituted with imidazolyl; or a radical of the formula: -Alk-O-CO-Ar ; or R and R taken together with the nitrogen atom to which they are attached may form an optionally substituted pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group; Ar is a phenyl, substituted phenyl, pyridinyl or substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).
    • 本发明涉及包括立体异构体及其药学上可接受的酸加成盐形式的式(I)化合物,其中X是S,SO或SO 2; R 1是NR 4 R 5或OR 5; R 2是C 1-6烷基,C 1-6烷氧基或C 1-6烷硫基; R 3是氢,C 1-6烷基,C 1-6烷基磺酰基,C 1-6烷基磺酰基或C 1-6烷硫基; R 4是氢,C 1-6烷基,一或二(C 3-6环烷基)甲基,C 3-6环烷基,C 3-6烯基,羟基C 1-6烷基,C 1-6烷基羰基氧基C 1-6烷基或C 1-6烷氧基C 1-6烷基; R 5是C 1-8烷基,单或二(C 3-6环烷基)甲基,Ar 1 CH 2,C 1-6烷氧基-C 1-6烷基,羟基C 1-6烷基,C 3-6烯基,噻吩基甲基,呋喃基甲基,C 1-6烷硫基C 1 -C 6烷基, (C 1-6烷基)氨基C 1-6烷基,二(C 1-6烷基)氨基,C 1-6烷基羰基C 1-6烷基,被咪唑基取代的C 1-6烷基; 或下式的基团:-Alk-O-CO-Ar 1; 或R 4和R 5与它们所连接的氮原子一起可以形成任选取代的吡咯烷基,哌啶基,高哌啶基或吗啉基; Ar是苯基,取代的苯基,吡啶基或取代的吡啶基; 具有CRF受体拮抗特性; 含有这些化合物作为活性成分的药物组合物; 通过施用有效量的式(I)化合物来治疗与CRF过度分泌有关的疾病的方法,例如抑郁症,焦虑症,药物滥用。